Key clinical point: In patients with constipation-predominant irritable bowel syndrome (IBS-C), short-term treatment with probiotics vs placebo led to a significant improvement in stool consistency and increased the number of fecal bacteria without increasing adverse events.

Major finding: Probiotics vs placebo significantly improved stool consistency (mean difference [MD] 0.71; P < .05) in 8 weeks and increased the number of fecal Bifidobacterium (MD 1.76; P < .05) and Lactobacillus (MD 1.69; P < .05) in 4 weeks, although the effects were not significant with longer treatment duration. Adverse effects were not significantly different between the probiotic and placebo groups.

Study details Findings are from a systematic review and meta-analysis of 10 randomized controlled trials including 757 patients with IBS-C.

Disclosures: This study was supported by the National Natural Science Foundation of China, the Gansu Special Project of Soft Science, and others. The authors declared no conflicts of interest.

Source: Shang X et al. Effectiveness and safety of probiotics for patients with constipation-predominant irritable bowel syndrome: A systematic review and meta-analysis of 10 randomized controlled trials. Nutrients. 2022;14(12):2482 (Jun 15). Doi: 10.3390/nu14122482

Key clinical point: In patients with constipation-predominant irritable bowel syndrome (IBS-C), short-term treatment with probiotics vs placebo led to a significant improvement in stool consistency and increased the number of fecal bacteria without increasing adverse events.

Major finding: Probiotics vs placebo significantly improved stool consistency (mean difference [MD] 0.71; P < .05) in 8 weeks and increased the number of fecal Bifidobacterium (MD 1.76; P < .05) and Lactobacillus (MD 1.69; P < .05) in 4 weeks, although the effects were not significant with longer treatment duration. Adverse effects were not significantly different between the probiotic and placebo groups.

Study details Findings are from a systematic review and meta-analysis of 10 randomized controlled trials including 757 patients with IBS-C.

Disclosures: This study was supported by the National Natural Science Foundation of China, the Gansu Special Project of Soft Science, and others. The authors declared no conflicts of interest.

Source: Shang X et al. Effectiveness and safety of probiotics for patients with constipation-predominant irritable bowel syndrome: A systematic review and meta-analysis of 10 randomized controlled trials. Nutrients. 2022;14(12):2482 (Jun 15). Doi: 10.3390/nu14122482

Key clinical point: In patients with constipation-predominant irritable bowel syndrome (IBS-C), short-term treatment with probiotics vs placebo led to a significant improvement in stool consistency and increased the number of fecal bacteria without increasing adverse events.

Major finding: Probiotics vs placebo significantly improved stool consistency (mean difference [MD] 0.71; P < .05) in 8 weeks and increased the number of fecal Bifidobacterium (MD 1.76; P < .05) and Lactobacillus (MD 1.69; P < .05) in 4 weeks, although the effects were not significant with longer treatment duration. Adverse effects were not significantly different between the probiotic and placebo groups.

Study details Findings are from a systematic review and meta-analysis of 10 randomized controlled trials including 757 patients with IBS-C.

Disclosures: This study was supported by the National Natural Science Foundation of China, the Gansu Special Project of Soft Science, and others. The authors declared no conflicts of interest.

Source: Shang X et al. Effectiveness and safety of probiotics for patients with constipation-predominant irritable bowel syndrome: A systematic review and meta-analysis of 10 randomized controlled trials. Nutrients. 2022;14(12):2482 (Jun 15). Doi: 10.3390/nu14122482

Key clinical point: Food supplements containing standardized menthol, limonene, and gingerol content significantly improved the efficacy of standard treatment in patients with irritable bowel syndrome (IBS) or IBS/functional dyspepsia (FD) without causing any obvious side effects.

Major finding: At visit 1 (before treatment), the median 7×7 questionnaire score of all patients indicated moderate illness. However, at visit 3, the score range indicated borderline illness in patients who received the food supplement and mild illness in those who received placebo (mean difference, −2.68; P  =  .009). No side effects were reported.

Study details Findings are from a randomized controlled trial including 56 patients with IBS or IBS/FD who were randomly assigned to receive food supplements or placebo in addition to the standard treatment regimen for 30 days.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Ivashkin VT et al. Efficacy and safety of a food supplement with standardized menthol, limonene, and gingerol content in patients with irritable bowel syndrome: A double-blind, randomized, placebo-controlled trial. PloS One. 2022;17(6):e0263880 (Jun 15). Doi: 10.1371/journal.pone.0263880

Key clinical point: Food supplements containing standardized menthol, limonene, and gingerol content significantly improved the efficacy of standard treatment in patients with irritable bowel syndrome (IBS) or IBS/functional dyspepsia (FD) without causing any obvious side effects.

Major finding: At visit 1 (before treatment), the median 7×7 questionnaire score of all patients indicated moderate illness. However, at visit 3, the score range indicated borderline illness in patients who received the food supplement and mild illness in those who received placebo (mean difference, −2.68; P  =  .009). No side effects were reported.

Study details Findings are from a randomized controlled trial including 56 patients with IBS or IBS/FD who were randomly assigned to receive food supplements or placebo in addition to the standard treatment regimen for 30 days.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Ivashkin VT et al. Efficacy and safety of a food supplement with standardized menthol, limonene, and gingerol content in patients with irritable bowel syndrome: A double-blind, randomized, placebo-controlled trial. PloS One. 2022;17(6):e0263880 (Jun 15). Doi: 10.1371/journal.pone.0263880

Key clinical point: Food supplements containing standardized menthol, limonene, and gingerol content significantly improved the efficacy of standard treatment in patients with irritable bowel syndrome (IBS) or IBS/functional dyspepsia (FD) without causing any obvious side effects.

Major finding: At visit 1 (before treatment), the median 7×7 questionnaire score of all patients indicated moderate illness. However, at visit 3, the score range indicated borderline illness in patients who received the food supplement and mild illness in those who received placebo (mean difference, −2.68; P  =  .009). No side effects were reported.

Study details Findings are from a randomized controlled trial including 56 patients with IBS or IBS/FD who were randomly assigned to receive food supplements or placebo in addition to the standard treatment regimen for 30 days.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Ivashkin VT et al. Efficacy and safety of a food supplement with standardized menthol, limonene, and gingerol content in patients with irritable bowel syndrome: A double-blind, randomized, placebo-controlled trial. PloS One. 2022;17(6):e0263880 (Jun 15). Doi: 10.1371/journal.pone.0263880

Key clinical point: Patients with diarrhea-predominant irritable bowel syndrome (IBS-D) vs healthy controls had lower serum zinc levels and poor scores for the quality of life (QoL) and physical and psychological health, and higher scores for depression, anxiety, and stress.

Major finding: Patients with IBS-D vs healthy controls reported significantly lower serum zinc levels (P  =  .001); mean scores for overall QoL and general health (53.48 vs 72.74; P ≤ .001), physical health (59.59 vs 71.30; P ≤ .001), and psychological health (55.80 vs 65.22; P ≤ .001); and higher mean scores for depression (P  =  .014), anxiety (P  =  .005), and stress (P  =  .001). Higher dietary zinc intake improved body image in patients with IBS-D (r 0.266; P  =  .044) without significantly influencing other parameters.

Study details: This was a case-control study including patients newly diagnosed with IBS-D (n = 61) and matched healthy controls (n = 61).

Disclosures: This study was supported by the Vice-Chancellor for Research of Isfahan University of Medical Sciences. The authors declared no conflicts of interest.

Source: Rezazadegan M et al. Sci Rep. 2022 Jun 29. doi: 10.1038/s41598-022-15080-2.

Key clinical point: Patients with diarrhea-predominant irritable bowel syndrome (IBS-D) vs healthy controls had lower serum zinc levels and poor scores for the quality of life (QoL) and physical and psychological health, and higher scores for depression, anxiety, and stress.

Major finding: Patients with IBS-D vs healthy controls reported significantly lower serum zinc levels (P  =  .001); mean scores for overall QoL and general health (53.48 vs 72.74; P ≤ .001), physical health (59.59 vs 71.30; P ≤ .001), and psychological health (55.80 vs 65.22; P ≤ .001); and higher mean scores for depression (P  =  .014), anxiety (P  =  .005), and stress (P  =  .001). Higher dietary zinc intake improved body image in patients with IBS-D (r 0.266; P  =  .044) without significantly influencing other parameters.

Study details: This was a case-control study including patients newly diagnosed with IBS-D (n = 61) and matched healthy controls (n = 61).

Disclosures: This study was supported by the Vice-Chancellor for Research of Isfahan University of Medical Sciences. The authors declared no conflicts of interest.

Source: Rezazadegan M et al. Sci Rep. 2022 Jun 29. doi: 10.1038/s41598-022-15080-2.

Key clinical point: Patients with diarrhea-predominant irritable bowel syndrome (IBS-D) vs healthy controls had lower serum zinc levels and poor scores for the quality of life (QoL) and physical and psychological health, and higher scores for depression, anxiety, and stress.

Major finding: Patients with IBS-D vs healthy controls reported significantly lower serum zinc levels (P  =  .001); mean scores for overall QoL and general health (53.48 vs 72.74; P ≤ .001), physical health (59.59 vs 71.30; P ≤ .001), and psychological health (55.80 vs 65.22; P ≤ .001); and higher mean scores for depression (P  =  .014), anxiety (P  =  .005), and stress (P  =  .001). Higher dietary zinc intake improved body image in patients with IBS-D (r 0.266; P  =  .044) without significantly influencing other parameters.

Study details: This was a case-control study including patients newly diagnosed with IBS-D (n = 61) and matched healthy controls (n = 61).

Disclosures: This study was supported by the Vice-Chancellor for Research of Isfahan University of Medical Sciences. The authors declared no conflicts of interest.

Source: Rezazadegan M et al. Sci Rep. 2022 Jun 29. doi: 10.1038/s41598-022-15080-2.

Key clinical point: Compared with the control diet, a diet low in fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAP) reduced the abundance of Bifidobacteria in the colonic microbiome of patients with irritable bowel syndrome (IBS), with no significant impact on other microbiome metrics.

Major finding: Overall, a low FODMAP diet had no clear impact on the microbiome biodiversity, total fecal short-chain fatty acid concentration (P  =  .20), and fecal pH (P  =  .14) compared with the control diet, but it was consistently associated with a reduced abundance of Bifidobacteria in the colonic microbiome.

Study details: Findings are from a systematic review and meta-analysis of 9 randomized controlled trials and 1 secondary publication including 403 patients with IBS who received a low FODMAP or control diet.

Disclosures: This study did not receive any funding. D So declared working in a department benefitting from the sales of a digital application and booklets on a low FODMAP diet.

Source: So D et al. Effects of a low FODMAP diet on the colonic microbiome in irritable bowel syndrome: A systematic review with meta-analysis. Am J Clin Nutr. 2022 (Jun 21). Doi:  10.1093/ajcn/nqac176

Key clinical point: Compared with the control diet, a diet low in fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAP) reduced the abundance of Bifidobacteria in the colonic microbiome of patients with irritable bowel syndrome (IBS), with no significant impact on other microbiome metrics.

Major finding: Overall, a low FODMAP diet had no clear impact on the microbiome biodiversity, total fecal short-chain fatty acid concentration (P  =  .20), and fecal pH (P  =  .14) compared with the control diet, but it was consistently associated with a reduced abundance of Bifidobacteria in the colonic microbiome.

Study details: Findings are from a systematic review and meta-analysis of 9 randomized controlled trials and 1 secondary publication including 403 patients with IBS who received a low FODMAP or control diet.

Disclosures: This study did not receive any funding. D So declared working in a department benefitting from the sales of a digital application and booklets on a low FODMAP diet.

Source: So D et al. Effects of a low FODMAP diet on the colonic microbiome in irritable bowel syndrome: A systematic review with meta-analysis. Am J Clin Nutr. 2022 (Jun 21). Doi:  10.1093/ajcn/nqac176

Key clinical point: Compared with the control diet, a diet low in fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAP) reduced the abundance of Bifidobacteria in the colonic microbiome of patients with irritable bowel syndrome (IBS), with no significant impact on other microbiome metrics.

Major finding: Overall, a low FODMAP diet had no clear impact on the microbiome biodiversity, total fecal short-chain fatty acid concentration (P  =  .20), and fecal pH (P  =  .14) compared with the control diet, but it was consistently associated with a reduced abundance of Bifidobacteria in the colonic microbiome.

Study details: Findings are from a systematic review and meta-analysis of 9 randomized controlled trials and 1 secondary publication including 403 patients with IBS who received a low FODMAP or control diet.

Disclosures: This study did not receive any funding. D So declared working in a department benefitting from the sales of a digital application and booklets on a low FODMAP diet.

Source: So D et al. Effects of a low FODMAP diet on the colonic microbiome in irritable bowel syndrome: A systematic review with meta-analysis. Am J Clin Nutr. 2022 (Jun 21). Doi:  10.1093/ajcn/nqac176

Key clinical point: In patients with irritable bowel syndrome with diarrhea (IBS-D), enterosgel vs placebo significantly improved abdominal pain and stool consistency, along with improving global symptoms and demonstrating a favorable safety profile.

Major finding: Significantly higher proportion of patients receiving enterosgel vs placebo showed response for the composite of abdominal pain and stool consistency during at least 4 weeks in the 8-week treatment period (37.4% vs 24.3%; adjusted odds ratio 1.95; P  =  .0020), with significant benefits for bloating (P  =  .0021), urgency (P < .0001), and loperamide use (P  =  .0049), and adequate relief from symptoms (P < .0001) in weeks 1-8. There were no enterosgel-related serious adverse events.

Study details Findings are from a randomized controlled trial including 431 patients with IBS-D who received enterosgel or placebo.

Disclosures: This study was funded by Bioline Products s.r.o. E Markaryan declared being the CEO of Enteromed, the study sponsor. CA Howell declared being an employee of Enteromed. The other authors declared being subcontracted by the sponsor or serving as chief investigator or trial steering committee members.

Source: Howell CA et al. Double-blinded randomised placebo controlled trial of enterosgel (polymethylsiloxane polyhydrate) for the treatment of IBS with diarrhoea (IBS-D). Gut. 2022 (Jun 27). Doi: 10.1136/gutjnl-2022-327293

Key clinical point: In patients with irritable bowel syndrome with diarrhea (IBS-D), enterosgel vs placebo significantly improved abdominal pain and stool consistency, along with improving global symptoms and demonstrating a favorable safety profile.

Major finding: Significantly higher proportion of patients receiving enterosgel vs placebo showed response for the composite of abdominal pain and stool consistency during at least 4 weeks in the 8-week treatment period (37.4% vs 24.3%; adjusted odds ratio 1.95; P  =  .0020), with significant benefits for bloating (P  =  .0021), urgency (P < .0001), and loperamide use (P  =  .0049), and adequate relief from symptoms (P < .0001) in weeks 1-8. There were no enterosgel-related serious adverse events.

Study details Findings are from a randomized controlled trial including 431 patients with IBS-D who received enterosgel or placebo.

Disclosures: This study was funded by Bioline Products s.r.o. E Markaryan declared being the CEO of Enteromed, the study sponsor. CA Howell declared being an employee of Enteromed. The other authors declared being subcontracted by the sponsor or serving as chief investigator or trial steering committee members.

Source: Howell CA et al. Double-blinded randomised placebo controlled trial of enterosgel (polymethylsiloxane polyhydrate) for the treatment of IBS with diarrhoea (IBS-D). Gut. 2022 (Jun 27). Doi: 10.1136/gutjnl-2022-327293

Key clinical point: In patients with irritable bowel syndrome with diarrhea (IBS-D), enterosgel vs placebo significantly improved abdominal pain and stool consistency, along with improving global symptoms and demonstrating a favorable safety profile.

Major finding: Significantly higher proportion of patients receiving enterosgel vs placebo showed response for the composite of abdominal pain and stool consistency during at least 4 weeks in the 8-week treatment period (37.4% vs 24.3%; adjusted odds ratio 1.95; P  =  .0020), with significant benefits for bloating (P  =  .0021), urgency (P < .0001), and loperamide use (P  =  .0049), and adequate relief from symptoms (P < .0001) in weeks 1-8. There were no enterosgel-related serious adverse events.

Study details Findings are from a randomized controlled trial including 431 patients with IBS-D who received enterosgel or placebo.

Disclosures: This study was funded by Bioline Products s.r.o. E Markaryan declared being the CEO of Enteromed, the study sponsor. CA Howell declared being an employee of Enteromed. The other authors declared being subcontracted by the sponsor or serving as chief investigator or trial steering committee members.

Source: Howell CA et al. Double-blinded randomised placebo controlled trial of enterosgel (polymethylsiloxane polyhydrate) for the treatment of IBS with diarrhoea (IBS-D). Gut. 2022 (Jun 27). Doi: 10.1136/gutjnl-2022-327293

Key clinical point: Transcutaneous electrical acustimulation (TEA) at the ST36 and PC6 acupuncture points improved symptoms of constipation and abdominal pain in patients with irritable bowel syndrome with constipation (IBS-C).

Major finding: The number of complete spontaneous bowel movements (CSBM) per week during the fourth week of treatment was significantly higher in the TEA vs sham-TEA group (3.5 ± 1.6 vs 2.3 ± 0.6; P  =  .002), with 44.0% vs 4.2% of patients reporting ≥3 CSBM/week (P  =  .001). TEA led to significant improvements in visual analog scale pain score (P  =  .002) and IBS-Severity Scoring System score (P  =  .025).

Study details: Findings are from a randomized controlled trial including 52 patients with IBS-C who were randomly assigned to receive either TEA or sham-TEA daily for 4 weeks.

Disclosures: This study was funded by the National Natural Science Foundation of China and Zhejiang Medical and Health Science and Technology Project. The authors declared no conflicts of interest.

Source: Huang Z et al. Transcutaneous electrical acustimulation improves irritable bowel syndrome with constipation by accelerating colon transit and reducing rectal sensation via autonomic mechanisms. Am J Gastroenterol. 2022 (Jun 17). Doi:  10.14309/ajg.0000000000001882

Key clinical point: Transcutaneous electrical acustimulation (TEA) at the ST36 and PC6 acupuncture points improved symptoms of constipation and abdominal pain in patients with irritable bowel syndrome with constipation (IBS-C).

Major finding: The number of complete spontaneous bowel movements (CSBM) per week during the fourth week of treatment was significantly higher in the TEA vs sham-TEA group (3.5 ± 1.6 vs 2.3 ± 0.6; P  =  .002), with 44.0% vs 4.2% of patients reporting ≥3 CSBM/week (P  =  .001). TEA led to significant improvements in visual analog scale pain score (P  =  .002) and IBS-Severity Scoring System score (P  =  .025).

Study details: Findings are from a randomized controlled trial including 52 patients with IBS-C who were randomly assigned to receive either TEA or sham-TEA daily for 4 weeks.

Disclosures: This study was funded by the National Natural Science Foundation of China and Zhejiang Medical and Health Science and Technology Project. The authors declared no conflicts of interest.

Source: Huang Z et al. Transcutaneous electrical acustimulation improves irritable bowel syndrome with constipation by accelerating colon transit and reducing rectal sensation via autonomic mechanisms. Am J Gastroenterol. 2022 (Jun 17). Doi:  10.14309/ajg.0000000000001882

Key clinical point: Transcutaneous electrical acustimulation (TEA) at the ST36 and PC6 acupuncture points improved symptoms of constipation and abdominal pain in patients with irritable bowel syndrome with constipation (IBS-C).

Major finding: The number of complete spontaneous bowel movements (CSBM) per week during the fourth week of treatment was significantly higher in the TEA vs sham-TEA group (3.5 ± 1.6 vs 2.3 ± 0.6; P  =  .002), with 44.0% vs 4.2% of patients reporting ≥3 CSBM/week (P  =  .001). TEA led to significant improvements in visual analog scale pain score (P  =  .002) and IBS-Severity Scoring System score (P  =  .025).

Study details: Findings are from a randomized controlled trial including 52 patients with IBS-C who were randomly assigned to receive either TEA or sham-TEA daily for 4 weeks.

Disclosures: This study was funded by the National Natural Science Foundation of China and Zhejiang Medical and Health Science and Technology Project. The authors declared no conflicts of interest.

Source: Huang Z et al. Transcutaneous electrical acustimulation improves irritable bowel syndrome with constipation by accelerating colon transit and reducing rectal sensation via autonomic mechanisms. Am J Gastroenterol. 2022 (Jun 17). Doi:  10.14309/ajg.0000000000001882

Key clinical point: Fecal microbiota transplantation (FMT) was safe and effective with effects sustained for at least 3 years after transplantation in patients with irritable bowel syndrome (IBS).

Major finding: Patients who received 30 or 60 g feces vs placebo showed a significantly higher response rate and significantly lower IBS-Severity Scoring System scores at 2 and 3 years after FMT (all P ≤ .05). No adverse event other than mild intermittent abdominal pain, diarrhea, and constipation within the first 2 days after FMT were reported.

Study details: Findings are from a 3-year follow-up study of 125 patients with IBS who underwent FMT and were randomly assigned to receive placebo (own feces) or donor feces (30 or 60 g); feces were administered to the duodenum.

Disclosures: This study was supported by Helse Fonna. The authors declared no conflicts of interest.

Source: El-Salhy M et al. Efficacy of fecal microbiota transplantation for patients with irritable bowel syndrome at three years after transplantation. Gastroenterology. 2022 (Jun 13). Doi:  10.1053/j.gastro.2022.06.020

Key clinical point: Fecal microbiota transplantation (FMT) was safe and effective with effects sustained for at least 3 years after transplantation in patients with irritable bowel syndrome (IBS).

Major finding: Patients who received 30 or 60 g feces vs placebo showed a significantly higher response rate and significantly lower IBS-Severity Scoring System scores at 2 and 3 years after FMT (all P ≤ .05). No adverse event other than mild intermittent abdominal pain, diarrhea, and constipation within the first 2 days after FMT were reported.

Study details: Findings are from a 3-year follow-up study of 125 patients with IBS who underwent FMT and were randomly assigned to receive placebo (own feces) or donor feces (30 or 60 g); feces were administered to the duodenum.

Disclosures: This study was supported by Helse Fonna. The authors declared no conflicts of interest.

Source: El-Salhy M et al. Efficacy of fecal microbiota transplantation for patients with irritable bowel syndrome at three years after transplantation. Gastroenterology. 2022 (Jun 13). Doi:  10.1053/j.gastro.2022.06.020

Key clinical point: Fecal microbiota transplantation (FMT) was safe and effective with effects sustained for at least 3 years after transplantation in patients with irritable bowel syndrome (IBS).

Major finding: Patients who received 30 or 60 g feces vs placebo showed a significantly higher response rate and significantly lower IBS-Severity Scoring System scores at 2 and 3 years after FMT (all P ≤ .05). No adverse event other than mild intermittent abdominal pain, diarrhea, and constipation within the first 2 days after FMT were reported.

Study details: Findings are from a 3-year follow-up study of 125 patients with IBS who underwent FMT and were randomly assigned to receive placebo (own feces) or donor feces (30 or 60 g); feces were administered to the duodenum.

Disclosures: This study was supported by Helse Fonna. The authors declared no conflicts of interest.

Source: El-Salhy M et al. Efficacy of fecal microbiota transplantation for patients with irritable bowel syndrome at three years after transplantation. Gastroenterology. 2022 (Jun 13). Doi:  10.1053/j.gastro.2022.06.020

Key clinical point: Risk for cutaneous infectious diseases is significantly higher in adults and children with atopic dermatitis (AD) than individuals without AD, with the risk for molluscum contagiosum being the highest.

Major finding: Patients with AD vs individuals without AD were at a significantly greater risk for molluscum contagiosum (adjusted odds ratio [aOR] 5.237), followed by impetigo (aOR 2.852), chickenpox (aOR 2.251), otitis media (aOR 2.243), eczema herpeticum (aOR 1.292), viral warts (aOR 1.105), and viral conjunctivitis (aOR 1.099; all P < .001) with molluscum contagiosum having the highest comorbidity (1.06%) and shortest onset duration (77.42 days).

Study details: Findings are from a nationwide population-based study including 70,205 patients with AD and individuals without AD.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Han J-H et al. Evaluation of atopic dermatitis and cutaneous infectious disorders using sequential pattern mining: A nationwide population-based cohort study. J Clin Med. 2022;11(12):3422 (Jun 14). Doi: 10.3390/jcm11123422

Key clinical point: Risk for cutaneous infectious diseases is significantly higher in adults and children with atopic dermatitis (AD) than individuals without AD, with the risk for molluscum contagiosum being the highest.

Major finding: Patients with AD vs individuals without AD were at a significantly greater risk for molluscum contagiosum (adjusted odds ratio [aOR] 5.237), followed by impetigo (aOR 2.852), chickenpox (aOR 2.251), otitis media (aOR 2.243), eczema herpeticum (aOR 1.292), viral warts (aOR 1.105), and viral conjunctivitis (aOR 1.099; all P < .001) with molluscum contagiosum having the highest comorbidity (1.06%) and shortest onset duration (77.42 days).

Study details: Findings are from a nationwide population-based study including 70,205 patients with AD and individuals without AD.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Han J-H et al. Evaluation of atopic dermatitis and cutaneous infectious disorders using sequential pattern mining: A nationwide population-based cohort study. J Clin Med. 2022;11(12):3422 (Jun 14). Doi: 10.3390/jcm11123422

Key clinical point: Risk for cutaneous infectious diseases is significantly higher in adults and children with atopic dermatitis (AD) than individuals without AD, with the risk for molluscum contagiosum being the highest.

Major finding: Patients with AD vs individuals without AD were at a significantly greater risk for molluscum contagiosum (adjusted odds ratio [aOR] 5.237), followed by impetigo (aOR 2.852), chickenpox (aOR 2.251), otitis media (aOR 2.243), eczema herpeticum (aOR 1.292), viral warts (aOR 1.105), and viral conjunctivitis (aOR 1.099; all P < .001) with molluscum contagiosum having the highest comorbidity (1.06%) and shortest onset duration (77.42 days).

Study details: Findings are from a nationwide population-based study including 70,205 patients with AD and individuals without AD.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Han J-H et al. Evaluation of atopic dermatitis and cutaneous infectious disorders using sequential pattern mining: A nationwide population-based cohort study. J Clin Med. 2022;11(12):3422 (Jun 14). Doi: 10.3390/jcm11123422

Key clinical point: Exposure to antibiotics in early life was not associated with an increased risk of development of atopic dermatitis (AD) from 1 year of life up to adolescence.

Major finding: Antibiotic exposure vs no exposure during the first 6 months of life (adjusted hazard ratio [aHR] 1.05; 95% CI 0.97-1.12), first year of life (aHR 1.02; 95% CI 0.97-1.07), and first 2 years of life (aHR 1.01; 95% CI 0.94-1.10) was not associated with an increased risk of development of AD.

Study details: Findings are from a retrospective study including 73,816 children aged 0-14 years, of which 34,202 were exposed to antibiotics.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Cantarutti A et al. Early-life exposure to antibiotics and subsequent development of atopic dermatitis. Expert Rev Clin Pharmacol. 2022 (Jun 20). Doi: 10.1080/17512433.2022.2092471

Key clinical point: Exposure to antibiotics in early life was not associated with an increased risk of development of atopic dermatitis (AD) from 1 year of life up to adolescence.

Major finding: Antibiotic exposure vs no exposure during the first 6 months of life (adjusted hazard ratio [aHR] 1.05; 95% CI 0.97-1.12), first year of life (aHR 1.02; 95% CI 0.97-1.07), and first 2 years of life (aHR 1.01; 95% CI 0.94-1.10) was not associated with an increased risk of development of AD.

Study details: Findings are from a retrospective study including 73,816 children aged 0-14 years, of which 34,202 were exposed to antibiotics.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Cantarutti A et al. Early-life exposure to antibiotics and subsequent development of atopic dermatitis. Expert Rev Clin Pharmacol. 2022 (Jun 20). Doi: 10.1080/17512433.2022.2092471

Key clinical point: Exposure to antibiotics in early life was not associated with an increased risk of development of atopic dermatitis (AD) from 1 year of life up to adolescence.

Major finding: Antibiotic exposure vs no exposure during the first 6 months of life (adjusted hazard ratio [aHR] 1.05; 95% CI 0.97-1.12), first year of life (aHR 1.02; 95% CI 0.97-1.07), and first 2 years of life (aHR 1.01; 95% CI 0.94-1.10) was not associated with an increased risk of development of AD.

Study details: Findings are from a retrospective study including 73,816 children aged 0-14 years, of which 34,202 were exposed to antibiotics.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Cantarutti A et al. Early-life exposure to antibiotics and subsequent development of atopic dermatitis. Expert Rev Clin Pharmacol. 2022 (Jun 20). Doi: 10.1080/17512433.2022.2092471

Key clinical point: Although food allergy (FA) is common among pediatric patients with atopic dermatitis (AD), immunoglobulin E (IgE) mediates the majority of instances and very few patients report food-triggered AD (FTAD), cautioning against unnecessary dietary restrictions.

Major finding: IgE-mediated FA was common in the overall cohort (55%) irrespective of the severity of AD (mild, 60%; moderate, 45%; severe, 57%), whereas FTAD was rare (3%) and diagnosed in only 2%, 6%, and 4% of patients with mild, moderate, and severe AD, respectively. In patients with AD only, more patients developed IgE-mediated FA vs FTAD (29% vs 5%).

Study details: Findings are from a retrospective study including 372 pediatric patients with AD, of which 29% had moderate AD and 18% had severe AD.

Disclosures: This study was funded by University of Wisconsin-Madison. The authors declared no conflicts of interest.

Source: Li JC et al. Prevalence of food allergy diagnosis in pediatric patients with atopic dermatitis referred to allergy and/or dermatology subspecialty clinics. J Allergy Clin Immunol Pract. 2022 (Jun 8). Doi: 10.1016/j.jaip.2022.05.028

Key clinical point: Although food allergy (FA) is common among pediatric patients with atopic dermatitis (AD), immunoglobulin E (IgE) mediates the majority of instances and very few patients report food-triggered AD (FTAD), cautioning against unnecessary dietary restrictions.

Major finding: IgE-mediated FA was common in the overall cohort (55%) irrespective of the severity of AD (mild, 60%; moderate, 45%; severe, 57%), whereas FTAD was rare (3%) and diagnosed in only 2%, 6%, and 4% of patients with mild, moderate, and severe AD, respectively. In patients with AD only, more patients developed IgE-mediated FA vs FTAD (29% vs 5%).

Study details: Findings are from a retrospective study including 372 pediatric patients with AD, of which 29% had moderate AD and 18% had severe AD.

Disclosures: This study was funded by University of Wisconsin-Madison. The authors declared no conflicts of interest.

Source: Li JC et al. Prevalence of food allergy diagnosis in pediatric patients with atopic dermatitis referred to allergy and/or dermatology subspecialty clinics. J Allergy Clin Immunol Pract. 2022 (Jun 8). Doi: 10.1016/j.jaip.2022.05.028

Key clinical point: Although food allergy (FA) is common among pediatric patients with atopic dermatitis (AD), immunoglobulin E (IgE) mediates the majority of instances and very few patients report food-triggered AD (FTAD), cautioning against unnecessary dietary restrictions.

Major finding: IgE-mediated FA was common in the overall cohort (55%) irrespective of the severity of AD (mild, 60%; moderate, 45%; severe, 57%), whereas FTAD was rare (3%) and diagnosed in only 2%, 6%, and 4% of patients with mild, moderate, and severe AD, respectively. In patients with AD only, more patients developed IgE-mediated FA vs FTAD (29% vs 5%).

Study details: Findings are from a retrospective study including 372 pediatric patients with AD, of which 29% had moderate AD and 18% had severe AD.

Disclosures: This study was funded by University of Wisconsin-Madison. The authors declared no conflicts of interest.

Source: Li JC et al. Prevalence of food allergy diagnosis in pediatric patients with atopic dermatitis referred to allergy and/or dermatology subspecialty clinics. J Allergy Clin Immunol Pract. 2022 (Jun 8). Doi: 10.1016/j.jaip.2022.05.028